Capsalus to Buy GeneWize's Sales and Marketing Business | GenomeWeb

By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Capsalus today said it has signed a letter of intent to buy the marketing rights and assets of GeneWize Life Sciences for an undisclosed amount.

GeneWize is the wholly-owned direct-selling subsidiary of consumer genomics firm GeneLink Biosciences and provides DNA customized nutritional supplements, skin care, and gene modulating weight management products.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Science this week: metagenomic-based technique for determining protein structure, and more.

An academic laments the rise of narcissism in the sciences, the Guardian reports.

Outgoing FDA commissioner Robert Califf writes in an editorial that the agency can help boost innovation.

The Trump transition team has asked NIH Director Francis Collins to remain at his post, though it's unclear for how long that will be.